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Introduction: Peripheral arterial disease (PAD) is associated with systemic impaired flow-mediated dilation (FMD) and
increased risk for cardiovascular events. Decreased FMD may be caused by a decrease in arterial shear stress due to
claudication and inflammation due to muscle ischemia and reperfusion. We assumed that endovascular revascularization
of lower limb arterial obstructions ameliorates FMD and lowers inflammation through improvement of peripheral
perfusion.
Methods: The study was a prospective, open, randomized, controlled, single-center follow-up evaluation assessing the
effect of endovascular revascularization on brachial artery reactivity (FMD) measured by ultrasound, white blood cell
(WBC) count, high-sensitive C-reactive protein (hs-CRP), and fibrinogen. We investigated 33 patients (23 men) with
chronic and stable PAD (Rutherford 2 to 3) due to femoropopliteal obstruction. Variables were assessed at baseline and
after 4 weeks in 17 patients (group A) who underwent endovascular revascularization and best medical treatment, and in
16 patients (group B) who received best medical treatment only.
Results: FMD did not differ between group A and B (4.96%  1.86% vs 4.60%  2.95%; P  .87) at baseline. It
significantly improved after revascularization in group A (6.44%  2.88%; P  .02) compared with group B at 4 weeks
of follow-up (4.53%  3.17%; P  .92), where it remained unchanged. The baseline ankle-brachial index (ABI) was
similar for group A and B (0.63 0.15 vs 0.66 0.10; P .36). At 4 weeks of follow-up, ABI was significantly increased
in group A (1.05  0.15; P  .0004) but remained unchanged in group B (0.62  0.1). WBC counts of the two groups
were comparable at baseline (group A: 7.6  2.26  106/mL and group B: 7.8  2.02  106/mL, P  .81). In group
A, the leukocyte count significantly decreased after angioplasty from 7.6 2.26 to 6.89 1.35 106/mL (P .03). For
group B, WBC count did not differ significantly compared with baseline (7.76  2.64  106/mL; P  .94). No effects
were observed on hs-CRP or fibrinogen from endovascular therapy.
Conclusion: Endovascular revascularization with reestablishment of peripheral arterial perfusion improves FMD and
reduces WBC count in patients with claudication. Revascularization may therefore have clinical implications beyond relief
of symptoms, for example, reducing oxidative stress caused by repeated muscle ischemia or increased shear stress due to
improved ambulatory activity. ( J Vasc Surg 2008;48:1211-6.)Peripheral arterial obstructive disease (PAOD) is a
common manifestation of atherosclerosis affecting 5% of
the aged population.1 Despite the low rate of peripheral
complications and amputation, PAOD is associated with a
minimal to severe impairment in functional activity and
with an increased risk of future cardiovascular events.2-5
For this reason, PAOD is considered a marker for systemic
atherosclerosis. To date the most powerful prognostic in-
dicator in PAOD patients is the ankle-brachial pressure
index (ABI).6
Recent data suggest that increased inflammatory activ-
ity and endothelial dysfunction could be linked in PAOD
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doi:10.1016/j.jvs.2008.06.039patients and affect cardiovascular outcomes.7,8 The degree
of elevation of white blood cell (WBC) count within the
normal range is a marker for increased risk for cardiovascu-
lar events in patients with PAOD.9,10 This had been attrib-
uted to repeated muscle ischemia producing oxidative
stress, with subsequent subclinical inflammatory activa-
tion.7,11-13 For example, treadmill exercise in these patients
is associated with a systemic inflammatory response14,15
and acute systemic endothelial dysfunction at distant
sites.12 Thus, the ischemia–reperfusion injury associated
with intermittent claudication could be among the causes
for increased inflammatory activity and endothelial dys-
function in PAOD patients.12,16,17
Claudication also results in decreased physical activity
and hence reduced shear stress.16 Repeated shear stress has
been shown to be one of the strongest stimuli for improve-
ment of endothelial function through an increase in nitric
oxide synthesis.17,18 The two factors, postischemic muscle
reperfusion and decreased shear stress, seem to be synergis-
tic causes for deterioration of endothelial function in
PAOD patients.
In recent years noninvasive ultrasound-based assess-
ment of brachial arterial flow-mediated dilatation
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impairment (endothelial dysfunction) consisting in a
decreased ability of the artery to dilated upon augmented
blood flow after a transient forearm ischemia.19 Impaired
FMD is thought to be linked to nitric oxide availability in
the endothelium.20 In addition, a predictive value of
FMD for cardiovascular events in patients with PAOD
has been reported recently.8,21
The aim of this study was to prospectively assess
whether the correction of intermittent leg ischemia by
endovascular revascularization is associated with a reduc-
tion in inflammatory mediators and thus an improvement
in endothelial function.
METHODS
Study design. The study was conducted at a tertiary
referral center as a prospective, open, randomized, con-
trolled, single-center follow-up evaluation assessing the
effect of lower limb endovascular revascularization on en-
dothelial dysfunction and inflammatory indicators (plas-
matic procoagulant activity) in patients with symptomatic
PAOD. Only patients with chronic and stable PAOD
(Rutherford class 2 to 3) due to femoropopliteal obstruc-
tion were eligible for the study.22 Exclusion criteria were
history of lower limb or coronary revascularization, acute
ischemic event within the last 3 months, chronic inflamma-
tory disorders, moderate or severe renal insufficiency, and
severe liver disease. Patients with incompressible tibial ar-
teries and persistent claudication after angioplasty were not
eligible for the study.
Randomization for angioplasty (group A) or conserva-
tive treatment (group B) was accomplished by a procedure
that used a random numeric sequence. The investigators
who performed FMD and laboratory analyses were blinded
to patient treatment allocation. The local ethic committee
approved the study, and all patients gave written informed
consent.
Assessment of brachial artery FMD, WBC count, high-
sensitive C-reactive protein (hs-CRP), and fibrinogen were
performed at baseline and at 4 weeks after randomization in
both groups. Before the investigations, patients were at rest
overnight and were not allowed to consume nicotine, caf-
feine, or to take vasoactive drugs for at least 10 hours before
the experiments and blood sampling. Patients were not
exposed to any other study drug or therapeutic treatment.
Endovascular procedures. Assessment before and af-
ter the intervention included clinical examination, Doppler
measurements of lower limb occlusive pressures with calcu-
lation of the ankle-brachial index (ABI), color duplex
sonography, and determination of routine laboratory tests.
Endovascular treatment was performed in the routine
manner. A 4F to 6F sheath that was compatible with an
over the wire low-profile dilation balloon and, occasionally,
an additional stenting system, which was at the discretion of
the interventionalist, was introduced antegrade into the
common femoral artery of the affected leg. After sheath
placement and diagnostic angiography, 5000 U of unfrac-
tionated heparin was injected intra-arterially.Postinterventional therapy lasted 4 weeks and consisted
of aspirin (100 mg/d) or clopidogrel (75 mg/d), or both
in case of stent insertion. To exclude any medication effects
on the investigated indicators, medication remained un-
changed except for clopidogrel in case of stent implantation
(2 patients). This medication was initiated after baseline
assessment and angioplasty with stent implantation and
lasted for 28 days.
Follow-up visits were done at day 30 to 32 after the
intervention. Successful angioplasty was defined by a final
angiogram with residual stenosis of 30% and postinter-
ventional ABI improvement of at least 0.1. In addition,
pain free walking distance was proven the day after the
procedure and at 30 to 32 days later by treadmill testing.
Assessment of FMD. Ultrasound assessment of
endothelial-dependent FMD of the brachial artery was done
according to recently reported guidelines.23 The study was per-
formed between 8 and 10 AM in a temperature-controlled room
(20° to 22°C)with subjects resting in a supine position. Brachial
diameter was imaged using a high-resolution (14-MHz line
array) transducer ultrasound system (Siemens, Erlangen, Ger-
many) equipped with electronic callipers, vascular software for
two-dimensional imaging, color and spectralDoppler, and inter-
nal electrocardiogram.
The brachial artery was imaged at a location 2 to 5 cm
above the cubital fossa. A sphygmomanometer cuff was
placed on the forearm. The cuff was inflated at least 50 mm
Hg above systolic pressure to occlude artery inflow for 5
minutes. All vasodilation measurements were made at the
end of diastole. Off-line measurements were performed on
a personal computer using the brachial reactivity analysis
software (Siemens). The response of the vessel diameter to
reactive hyperemia was calculated and expressed as a per-
centage change relative to the diameter immediately before
cuff inflation. Off-line analysis was performed by one oper-
ator (A. S.) in a blinded fashion.
Assessment of ABI and treadmill testing. The ABI
was calculated with the patient supine. The highest systolic
pressure of the anterior or posterior tibial artery was mea-
sured in each limb and was divided by the highest brachial
artery pressure. Standardized treadmill testing was per-
formed at 3.2 km/h and 12% inclination, 1 day postproce-
dure and 4 days later, to assess 10 minutes of pain-free
walking time in patients after angioplasty.
Biochemistry. Measurement of hs-CRP was done
using an immunoturbidimetric detection method
(Roche, Hitachi Modular P800, Basel, Switzerland).
Fibrinogen clotting was measured according to the
Clauss method on a Behring BCS coagulation analyzer
using Multifibren U (Dade Behring Diagnostics, Sie-
mens Healthcare Diagnostics, Deerfield, Ill).24 Platelet
and WBC counts were measured by an LH-750 and
LH-780 System (Beckman-Coulter Inc, Fullerton, Calif)
and ADVIA 120 Hematology system (Siemens Health-
care Diagnostics). Enzymatic methods were used to
measure plasma total cholesterol and triglycerides
(Roche). Low-density lipoprotein cholesterol was calcu-
lated using the Friedewald formula.25
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standard deviation (SD). Data were analyzed using the
Mann-Whitney U test for intergroup comparison and the
Wilcoxon signed rank test for intragroup comparison. Sam-
ple size calculation was based on data by Brendle et al,26
who demonstrated an improvement of FMD by 61% (from
0.18  0.03 to 0.29  0.04 mm) after a 6-month walking
exercise therapy. Assuming an effect size of 1.61 ( 0.05;
power 0.80, two-tailed) we calculated a sample size of 16
subjects per group. Expecting a drop-out rate of 20%, we
had to evaluate 42 patients (21 per group). Data were
analyzed with StatView 5.0.1 software (Adept Scientific,
Acton, Mass). A value of P  .05 was considered to be
significant.
RESULTS
Patient demographics. Nine patients were excluded
from the study, four from group A because of persistent
claudication after endovascular revascularization and five in
group B due to cardiovascular events before the follow-up
assessment. For analysis of indicators, only patients with
complete baseline and follow-up assessment were included,
resulting in 17 patients (group A) with successful angio-
plasty and subsequently pain-free walking distance during
10 minutes on the treadmill, and 16 patients in group B
with best medical treatment. Clinical baseline characteris-
tics did not differ among PAOD patients of both groups
(Table I). Patients in whom endovascular therapy was not
successful were not included.
Flow-mediated dilation. FMD did not differ signifi-
Table I. Clinical characteristics of patients with
peripheral arterial obstructive disease in group A





(n  16) P
Age, mean (range), years 66 (47-82) 72 (53-84) .25
Sex, No.
Males 11 6 .12
Females 6 10
Body mass index, kg/m2 26.2 26.8 .69
Hypertension, No. % 12 (71) 12 (75) .54
Diabetes mellitus, No. % 4 (24) 4 (25) .73
Dyslipidemia, No. % 9 (56) 11 (68) .10
Smoking, No. %
Active 8 (47) 8 (50)
Former 3 (18) 7 (44) .08
Never 6 (35) 1 (6)
Coronary artery disease, No. % 4 (23) 4 (25) .73
Cerebrovascular disease, No. % 3 (17) 0 (0) .10
Medication, No. %
Aspirin/clopidogrel 16 (94) 14 (87) .90
Oral anticoagulation 1 (6) 3 (13) .76
Statin 7 (41) 9 (56) .17
ACE inhibitor 7 (41) 6 (38) .89
Calcium antagonist 2 (11) 1 (6) .67
Angiotensin receptor
blocker 3 (17) 4 (25) .45
ACE, Angiotensin-converting enzyme.cantly between group A (4.96%  1.86%) and B (4.60% 2.95%) at baseline (P  .65). After successful endovascular
revascularization, FMD significantly increased in group
A compared with baseline (6.44%  2.88%; P  .02;
Fig 1). FMD of group B did not change during fol-
low-up (4.53%  3.17%; P  .92) and differed from
postinterventional FMD of group A, although this dif-
ference did not reach statistical significance (P  .09).
The ABI was similar for group A and B at baseline
(0.63  0.15 vs 0.66  0.10; P  .36). The ABI
significantly increased in group A after revascularization
(1.05  0.15; P  .0004) but remained unchanged in
group B at follow-up (0.62  0.1; P  .82).
Laboratory analysis. The WBC counts of the two
groups were comparable at baseline, at 7.6  2.26 
106/mL for group A and 7.8 2.02 106/mL for group
B (P .81; Fig 2). After angioplasty, a slight but significant
decrease occurred in the WBC count for group A (6.89 
1.35  106/mL, P  .03). For group B, WBC count did
not change significantly compared with baseline (7.76 
Fig 1. Endovascular revascularization in group A (black bars)
improved flow-mediated dilation compared with baseline (*P 
.02) and with group B (conservative treatment, white bars) at
follow-up (P  .09). Conservative treatment did not alter flow-
mediated dilation in group B (P  .92). Error bars show the
standard deviation.
Fig 2. Effect of angioplasty on white blood cell count on group A
(revascularization, black bars) and group B (conservative treat-
ment, white bars). Error bars show the standard deviation. *P 
.03 for group A compared with baseline.2.64  106/mL, P  .94). In contrast, there was no
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263  79  103/mL; group B, 225  85  103/mL) to
follow-up (group A, 260 85 103/mL; group B, 212
69  103/mL) or significant differences between the two
groups.
Although the levels of hs-CRP and fibrinogen were
slightly lower in both groups at follow-up, these differences
were not significant, nor did the values differ between the
groups at baseline or follow-up (Table II).
DISCUSSION
Patients with PAOD exhibit a marked deterioration of
FMD and increased levels of inflammatory and oxidative
stress markers, possibly due to the atherosclerotic burden,
muscle ischemia and reperfusion, and decreased shear stress
due to claudication.8,13,27-29 Furthermore, higher levels of
WBCs within the normal range were shown to be associ-
ated with poorer prognosis in PAOD patients.10,30 The
present study indicates that endovascular treatment of in-
termittent claudication ameliorates FMD and reduces
WBC count.
So far, a beneficial effect has only been shown for
antioxidative treatment in PAOD patients, which resulted
in a transient improvement of FMD.12,13,31 This is thought
to be due to the scavenging effects of antioxidants on
reactive oxygen species that result from reperfusion of
ischemic muscle. Successful revascularization attenuates
muscle ischemia and therefore generation of reactive oxy-
gen species and inflammation. Inflammation and free oxy-
gen radicals reduce nitric oxide bioavailability. The abolish-
ment of claudication and hence generation of reactive
oxygen species may partly explain our observation, because
FMD has been shown to closely correlate with nitric oxide
bioavailability.20
In addition, the limitation of physical activity by inter-
mittent claudication is relieved through successful endovas-
cular repair. Physical activity (ie, walking) has been shown
to be the main stimulus for endothelial-dependent vasodi-
Table II. Effect of angioplasty (group A) and
conservative treatment (group B) on high-sensitive
C-reactive protein and fibrinogen in patients with stable
symptomatic peripheral atherosclerotic disease
Indicator
Group A




Baseline 3.87  0.53 .48 4.24  0.69
Follow-up 3.54  0.54 .52 4.0  0.78
Pb .44 .41
Hs-CRP (mg/L)
Baseline 2.93  2.16 .46 2.67  1.12
Follow-up 2.39  1.46 .25 2.2  1.01
Pb .17 .28
Hs-CRP, High-sensitive C-reactive protein.
aIntergroup comparison.
bIntragroup comparison.latation through a rise in shear stress.32,33 An increase inendothelial nitric oxide synthesis is an important physio-
logic adaptation to regular exercise. Moreover, regular
exercise has been shown to improve vascular function in
adults independent of changes in other risk factors.34,35
Therefore, besides being of pathophysiologic interest, our
findings may also have a clinical application in that the
indication for endovascular treatment in patients with in-
termittent claudication may be expanded beyond simple
pain relief.
Epidemiologic studies have demonstrated a high prev-
alence of vascular events in patients with PAOD.3,36 Several
studies have clearly shown the importance of engaging in
regular exercise to attenuate or reverse the disease process
in patients with cardiovascular disease.37 Continuous walk-
ing, either three times for 60 minutes or six times for 30
minutes per week, had been proposed as being sufficient for
attenuation of atherosclerotic disease progression.38 It is
highly unlikely, however, that patients with PAOD and at
Rutherford stages 2 or 3 are able to walk for half an hour.
Studies on walking exercise in patients with PAOD dem-
onstrate an increase of up to 400% in pain-free walking
distance.39 This increasemay still be far beyond the capacity
to continuously walk for half an hour to provide a sufficient
stimulus for prolonged shear stress for sufficient effect on
nitric oxide synthesis.
In our study, endovascular therapy resulted in an in-
crease of walking capacity that was proven by treadmill
testing 4 weeks after the procedure. Increased physical
activity, although not quantified in our study, could explain
the changes found already after a 4-week follow-up. It is
well known that exercise training improves ambulatory
function collateralization, resulting in an improved pain-
free walking distance. The development of collateralization
is slow, however, whereas in contrast, successful angioplasty
reestablishes full walking capacity immediately. This facili-
tates physical activity.
Presently, it remains unclear whether the abolishment
of claudication and hence reduction in oxidative stress or
already increased physical activity explains a better FMD in
our study population. Provided the absence of additional
oxidative stress (ie, repeated muscle ischemia), it has been
shown that exercise affects FMD already after a short train-
ing time of 4 weeks.40
Other possible factors, such as vitamin supplementa-
tion or other medications with aspirin/clopidogrel, or
both, on FMD and WBC count are unlikely to have af-
fected the present findings because patients were asked to
continue their medication unchanged and to withhold any
supplementation. In two patients who had stent implanta-
tion, clopidogrel medication was ceased 2 to 4 days before
the follow-up assessment.
Findings of a reduced WBC count in our study may be
related to the abolishment of muscle ischemia after success-
ful revascularization. This is an important finding, because
the degree of elevation of WBC count within the normal
range is a marker for an increased risk of cardiovascular
events.10 In contrast, we did not find any changes in the
platelet count. Similarly, hs-CRP and fibrinogen remained
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due to reduction of inflammation might be expected. In
accordance with our findings of unchanged hs-CRP and
fibrinogen,Wahlgren et al41 reported a transient increase in
fibrinogen and hs-CRP levels within the first day after the
endovascular procedure, but these markers did not differ
from baseline values at the 1-month follow-up. The time
period in our study may have been too short, or the study
population too small, to reveal any beneficial effects of
increased physical activity or decreased oxidative stress, or
both, on hs-CRP and fibrinogen.
The lack of assessment of physical activity or markers of
oxidative stress is a shortcoming of the present study.
Future studies are needed to address these questions, both
in terms of pathophysiologic understanding and therapeu-
tic management of PAOD patients. Another limitation is
the lack of structured exercise training for both groups.
However, the extent of exercise training would then differ
with regard to absolute walking capacity between the two
groups, whereas the present scenario represents the real-
world setting. Nevertheless, the possible spontaneous in-
crease in physical activity, which is mainly attributable to
relief of symptoms in the angioplasty group, demonstrates
the importance of endovascular revascularization in terms
of freedom from pain that might be able to counteract a
sedentary lifestyle.
So far, the endovascular treatment for Rutherford
stages 2 to 3 was aimed to improve patients’ quality of life.
If PAOD is recognized as a restriction of physical activity in
a growing elderly population and endovascular or surgical
revascularization can be confirmed to increase physical
activity, thereby reducing cardiovascular morbidity and
mortality, additional systemic benefits of revascularization
in terms of public health economy may outweigh the initial
costs. Future randomized studies comparing conservative
vs endovascular therapy are warranted to confirm the
present findings in larger patient settings incorporating
cardiovascular end points.
In conclusion, endovascular revascularization for stable
claudication resulting in alleviation of symptoms improves
brachial artery endothelial function and decreases leukocyte
count.
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